Home > Portfolio > S*BIO Pte Ltd
Portfolio Companies

S*BIO Pte Ltd

URL: http://www.sbio.com/
Domain: Healthcare
Area: Others

S*BIO is developing several drug candidates, among which the flagship is SB1518, a JAK2 inhibitor in Phase I/II for CIMF. The second is SB939, a HDAC inhibitor in Phase I for Solid tumor.

Company S*BIO Pte Ltd
Business Drug discovery
URL http://www.sbio.com/
President & CEO Jan-Anders Karlsson
Establishment May 2000
Company Location 1 Science Park Road, #05-09 The Capricorn, Singapore Science Park II, Singapore

News Release

[09/27/2010]

S*BIO Initiates Canadian Phase 2 Clinical Trial of Oral Histone Deacetylase (HDAC) Inhibitor SB939 for the Treatment of Recurrent or Metastatic Prostate Cancer (HRPC)

[09/24/2010]

Mitsui Ventures invested USD 5 M in S*BIO

Mitsui Ventures invested approximately USD 5 million in S*BIO Pte Ltd through Mitsui Ventures Global Fund.

Portfolio Companies
  • United States
  • Japan
  • China
  • EMEA/Other
  • United States
  • Japan
  • China
  • EMEA/Other
  • United States
  • Japan
  • United States
  • China

News Release

09/27/2010 11/01/2010
MVC Corporation Changes Name to Mitsui & Co. Global Investment, Ltd. 09/27/2010 11/01/2010
MCVP Changes Name and Relocates Office 09/27/2010 09/27/2010
Notice on Relocation of MVC Head Office 09/24/2010 09/24/2010
Mitsui Ventures invested USD 5 M in S*BIO Taro Inaba 06/17/2008 | Taro Inaba
Boehringer Ingelheim announced an agreement to acquire Actimis Pharmaceuticals, Inc. one of our portfolio firms.